What it is:
An advanced biomaterial architecture and processing framework designed to fabricate highly porous, structurally optimized bioactive scaffolds. It utilizes engineered silica-based nanocomposites tailored to mimic extracellular matrix (ECM) microenvironments for accelerated cellular attachment and tissue regeneration.
Why it matters:
Traditional tissue engineering scaffolds often suffer from poor cellular infiltration, inadequate mechanical-to-biological property matching, and lack of precise signaling for localized cellular differentiation. AURASILICA overcomes these limitations by integrating dynamic surface functionalization with a tailored degradation rate, ensuring structural integrity while actively promoting native tissue integration without triggering adverse immunogenic responses.
How it works:
The technology relies on an optimized synthesis protocol that controls pores at the micro, meso, and macro-scale. This open-pore topology provides optimal mass transport for nutrients and oxygen. The bioactive surface chemistry is engineered to systematically release silicon ions at safe, therapeutic concentrations, stimulating osteogenic or tissue-specific signaling pathways while providing high-resolution geometric layouts for guided cell growth.
Proof to date:
Physicochemical and computational modeling have validated that AURASILICA maintains precise degradation kinetics aligned with typical cell proliferation timelines. Structural simulations confirm a high porosity-to-mechanical-strength ratio, ensuring the scaffold can withstand physiological loads during the initial cellular seeding and proliferation phases without structural collapse.
Next steps:
We are seeking sponsored research, clinical-track co-development, and academic partners to transition our validated structural concept into in vitro cell culture validation and biological assay testing. We are highly receptive to licensing and intellectual property partnership models.